Renal Failure is an indication for drug development with over 250 pipeline drugs currently active. According to GlobalData, preregistered drugs for Renal Failure have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Renal Failure compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Renal Failure overview
Renal failure, or kidney failure, occurs when the kidneys cannot perform essential functions, leading to the buildup of waste and fluids. It presents as acute or chronic, with distinct characteristics. Acute renal failure emerges suddenly, often from severe infections, dehydration, or abrupt blood flow loss to the kidneys. Conversely, chronic renal failure develops gradually, linked to conditions like diabetes or hypertension. Symptoms encompass reduced urine output, leg swelling, fatigue, confusion, and breathlessness. Diagnosis involves blood and urine tests, plus imaging studies. Management varies, addressing underlying issues for acute cases, and incorporating lifestyle changes, medications, or dialysis for chronic cases. Severe instances may necessitate kidney transplantation. Preventive measures involve managing health conditions, hydration, and a kidney-friendly lifestyle, emphasizing regular medical check-ups for early intervention and improved outcomes.
For a complete picture of PTSR and LoA scores for drugs in Renal Failure, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
